Patents by Inventor Johannes Gustaaf Ernst VAN LEEUWEN
Johannes Gustaaf Ernst VAN LEEUWEN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240067938Abstract: The present invention relates a variant polypeptide having geranylgeranyl pyrophosphate synthase activity, which variant polypeptide comprises an amino acid sequence which, when aligned with a geranylgeranyl pyrophosphate synthase comprising the sequence set out in SEQ ID NO: 1, comprises at least one substitution of an amino acid residue corresponding to any of amino acids at positions 92, 100 or 235 said positions being defined with reference to SEQ ID NO: 1 and wherein the variant has one or more modified properties as compared with a reference polypeptide having geranylgeranyl pyrophosphate synthase activity. A variant polypeptide of the invention may be used in a recombinant host for the production of steviol or a steviol glycoside.Type: ApplicationFiled: August 25, 2023Publication date: February 29, 2024Inventors: Viktor Marius BOER, Priscilla ZWARTJENS, Johannes Gustaaf Ernst VAN LEEUWEN
-
Patent number: 11913034Abstract: The present invention relates a polypeptide having kaurenoic acid 13-hydroxylase activity, which polypeptide comprises an amino acid sequence which, when aligned with a kaurenoic acid 13-hydroxylase comprising the sequence set out in SEQ ID NO: 1 or SEQ ID NO: 3, comprises at least one substitution of an amino acid corresponding to any of amino acids at positions 136, 248, 336 or 403, said positions being defined with reference to SEQ ID NO: 1 or SEQ ID NO: 3 and wherein the polypeptide has one or more modified properties as compared with a reference polypeptide having kaurenoic acid 13-hydroxylase activity. A polypeptide of the invention may be used in a recombinant host for the production of steviol or a steviol glycoside.Type: GrantFiled: July 21, 2021Date of Patent: February 27, 2024Assignee: DSM IP ASSETS B.V.Inventors: Johannes Gustaaf Ernst Van Leeuwen, Priscilla Zwartjens, Viktor Marius Boer
-
Publication number: 20240016195Abstract: Process comprising reducing a fermentation broth comprising 2?-fucosyllactose to produce a treated fermentation broth comprising 2?-fucosyllactose and 2?-fucosyllactitol; isolating a stream comprising 2?-fucosyllactose and 2?-fucosyllactitol from the treated fermentation broth; purifying the isolated stream; concentrating the purified isolated stream; dewatering the concentrated purified isolated stream, thereby forming a prebiotic solids product comprising 2?-fucosyllactose and 0.2 to 6.0 wt. % of 2?-fucosyllactitol based on the total wt. % of the prebiotic solids product, wherein the concentrating step and dewatering step can be performed in any order.Type: ApplicationFiled: December 7, 2021Publication date: January 18, 2024Inventors: Johannes Gustaaf Ernst VAN LEEUWEN, Frank WIENS, Marco Alexander VAN DEN BERG
-
Patent number: 11781121Abstract: The present invention relates a variant polypeptide having geranylgeranyl pyrophosphate synthase activity, which variant polypeptide comprises an amino acid sequence which, when aligned with a geranylgeranyl pyrophosphate synthase comprising the sequence set out in SEQ ID NO: 1, comprises at least one substitution of an amino acid residue corresponding to any of amino acids at positions 92, 100 or 235 said positions being defined with reference to SEQ ID NO: 1 and wherein the variant has one or more modified properties as compared with a reference polypeptide having geranylgeranyl pyrophosphate synthase activity. A variant polypeptide of the invention may be used in a recombinant host for the production of steviol or a steviol glycoside.Type: GrantFiled: December 3, 2021Date of Patent: October 10, 2023Assignee: DSM IP ASSETS B.V.Inventors: Viktor Marius Boer, Priscilla Zwartjens, Johannes Gustaaf Ernst Van Leeuwen
-
Publication number: 20230295586Abstract: The present disclosure relates a polypeptide having UGT activity, which polypeptide comprises an amino acid sequence which, when aligned with a polypeptide having UGT activity comprising the sequence set out in SEQ ID NO: 2, comprises at least one substitution of an amino acid corresponding to any of amino acids at positions 35, 189, 280, 284, 285, 334 or 373, said positions being defined with reference to SEQ ID NO: 2 and wherein the polypeptide has one or more modified properties as compared with a reference polypeptide having UGT activity. A polypeptide according to the disclosure may be used in a recombinant cell for the production of steviol or a steviol glycoside.Type: ApplicationFiled: March 20, 2023Publication date: September 21, 2023Inventors: Viktor Marius BOER, Johannes Gustaaf Ernst VAN LEEUWEN
-
Publication number: 20230227510Abstract: The disclosure provides a recombinant cell capable of producing a steviol glycoside, wherein the cell comprises a nucleic acid coding for a variant of a parent polypeptide, wherein the variant has steviol glycoside transport mediating activity, wherein the variant comprises an amino acid sequence which, when aligned with the amino acid sequence of the parent polypeptide, comprises at least one modification of the amino acid residue corresponding to any of the amino acids in the amino acid sequence of the parent polypeptide, wherein the variant has an improved ability to produce rebaudioside M and optionally other steviol glycosides extracellularly if compared with the parent polytpeptide when measured under the same conditions.Type: ApplicationFiled: February 10, 2023Publication date: July 20, 2023Inventors: Johannes Gustaaf Ernst VAN LEEUWEN, Viktor Marius BOER, Priscilla ZWARTJENS, Jos VAN VUGT, René Marcel DE JONG
-
Patent number: 11639497Abstract: The present disclosure relates a polypeptide having UGT activity, which polypeptide comprises an amino acid sequence which, when aligned with a polypeptide having UGT activity comprising the sequence set out in SEQ ID NO: 2, comprises at least one substitution of an amino acid corresponding to any of amino acids at positions 35, 189, 280, 284, 285, 334 or 373, said positions being defined with reference to SEQ ID NO: 2 and wherein the polypeptide has one or more modified properties as compared with a reference polypeptide having UGT activity. A polypeptide according to the disclosure may be used in a recombinant cell for the production of steviol or a steviol glycoside.Type: GrantFiled: June 26, 2018Date of Patent: May 2, 2023Assignee: DSM IP ASSETS B.V.Inventors: Viktor Marius Boer, Johannes Gustaaf Ernst Van Leeuwen
-
Patent number: 11608364Abstract: The disclosure provides a recombinant cell capable of producing a steviol glycoside, wherein the cell comprises a nucleic acid coding for a variant of a parent polypeptide, wherein the variant has steviol glycoside transport mediating activity, wherein the variant comprises an amino acid sequence which, when aligned with the amino acid sequence of the parent polypeptide, comprises at least one modification of the amino acid residue corresponding to any of the amino acids in the amino acid sequence of the parent polypeptide, wherein the variant has an improved ability to produce rebaudioside M and optionally other steviol glycosides extracellularly if compared with the parent polypeptide when measured under the same conditions.Type: GrantFiled: April 29, 2019Date of Patent: March 21, 2023Assignee: DSM IP ASSETS B.V.Inventors: Johannes Gustaaf Ernst Van Leeuwen, Viktor Marius Boer, Priscilla Zwartjens, Jos Van Vugt, René Marcel De Jong
-
Patent number: 11459548Abstract: The present invention relates to a recombinant host comprising a recombinant nucleic acid sequence encoding a polypeptide having at least about: a. 85% identity to the amino acid sequence set forth in SEQ ID NO: 1; b. 85% identity to the amino acid sequence set forth in SEQ ID NO: 3; c. 85% identity to the amino acid sequence set forth in SEQ ID NO: 6; d. 85% identity to the amino acid sequence set forth in SEQ ID NO: 9; e. 85% identity to the amino acid sequence set forth in SEQ ID NO: 11; f. 85% identity to the amino acid sequence set forth in SEQ ID NO: 14; g. 85% identity to the amino acid sequence set forth in SEQ ID NO: 17; h. 85% identity to the amino acid sequence set forth in SEQ ID NO: 20; i. 85% identity to the amino acid sequence set forth in SEQ ID NO: 22; or j. 85% identity to the amino acid sequence set forth in SEQ ID NO: 25.Type: GrantFiled: January 27, 2021Date of Patent: October 4, 2022Assignee: DSM IP ASSETS B.V.Inventors: Viktor Marius Boer, Johannes Gustaaf Ernst Van Leeuwen, Priscilla Zwartjens, Catharina Petronella Antonia Maria Kolen
-
Publication number: 20220090032Abstract: The present invention relates a variant polypeptide having geranylgeranyl pyrophosphate synthase activity, which variant polypeptide comprises an amino acid sequence which, when aligned with a geranylgeranyl pyrophosphate synthase comprising the sequence set out in SEQ ID NO: 1, comprises at least one substitution of an amino acid residue corresponding to any of amino acids at positions 92, 100 or 235 said positions being defined with reference to SEQ ID NO: 1 and wherein the variant has one or more modified properties as compared with a reference polypeptide having geranylgeranyl pyrophosphate synthase activity. A variant polypeptide of the invention may be used in a recombinant host for the production of steviol or a steviol glycoside.Type: ApplicationFiled: December 3, 2021Publication date: March 24, 2022Inventors: Viktor Marius BOER, Priscilla ZWARTJENS, Johannes Gustaaf Ernst VAN LEEUWEN
-
Patent number: 11225647Abstract: The present invention relates a variant polypeptide having geranylgeranyl pyrophosphate synthase activity, which variant polypeptide comprises an amino acid sequence which, when aligned with a geranylgeranyl pyrophosphate synthase comprising the sequence set out in SEQ ID NO: 1, comprises at least one substitution of an amino acid residue corresponding to any of amino acids at positions 92, 100 or 235 said positions being defined with reference to SEQ ID NO: 1 and wherein the variant has one or more modified properties as compared with a reference polypeptide having geranylgeranyl pyrophosphate synthase activity. A variant polypeptide of the invention may be used in a recombinant host for the production of steviol or a steviol glycoside.Type: GrantFiled: October 26, 2017Date of Patent: January 18, 2022Assignee: DSM IP ASSETS B.V.Inventors: Viktor Marius Boer, Priscilla Zwartjens, Johannes Gustaaf Ernst Van Leeuwen
-
Patent number: 11203764Abstract: The present invention relates a variant polypeptide having kaurenoic acid 13-hydroxylase activity, which variant polypeptide comprises an amino acid sequence which, when aligned with a kaurenoic acid 13-hydroxylase comprising the sequence set out in SEQ ID NO: 1, comprises at least one substitution of an amino acid residue corresponding to any of amino acids 72, 85, 108, 127, 129, 141, 172, 195, 196, 197, 199, 226, 236, 291, 302, 361 or 464, said positions being defined with reference to SEQ ID NO: 1 and wherein the variant has one or more modified properties as compared with a reference polypeptide having kaurenoic acid 13-hydroxylase activity. A variant polypeptide of the invention may be used in a recombinant host for the production of steviol or a steviol glycoside.Type: GrantFiled: July 24, 2020Date of Patent: December 21, 2021Assignee: DSM IP ASSETS B.V.Inventors: Johannes Gustaaf Ernst Van Leeuwen, Priscilla Zwartjens, Viktor Marius Boer
-
Publication number: 20210348136Abstract: The present invention relates a polypeptide having kaurenoic acid 13-hydroxylase activity, which polypeptide comprises an amino acid sequence which, when aligned with a kaurenoic acid 13-hydroxylase comprising the sequence set out in SEQ ID NO: 1 or SEQ ID NO: 3, comprises at least one substitution of an amino acid corresponding to any of amino acids at positions 136, 248, 336 or 403, said positions being defined with reference to SEQ ID NO: 1 or SEQ ID NO: 3 and wherein the polypeptide has one or more modified properties as compared with a reference polypeptide having kaurenoic acid 13-hydroxylase activity. A polypeptide of the invention may be used in a recombinant host for the production of steviol or a steviol glycoside.Type: ApplicationFiled: July 21, 2021Publication date: November 11, 2021Inventors: Johannes Gustaaf Ernst VAN LEEUWEN, Priscilla ZWARTJENS, Viktor Marius BOER
-
Patent number: 11104886Abstract: The present invention relates a polypeptide having kaurenoic acid 13-hydroxylase activity, which polypeptide comprises an amino acid sequence which, when aligned with a kaurenoic acid 13-hydroxylase comprising the sequence set out in SEQ ID NO: 1 or SEQ ID NO: 3, comprises at least one substitution of an amino acid corresponding to any of amino acids at positions 136, 248, 336 or 403, said positions being defined with reference to SEQ ID NO: 1 or SEQ ID NO: 3 and wherein the polypeptide has one or more modified properties as compared with a reference polypeptide having kaurenoic acid 13-hydroxylase activity. A polypeptide of the invention may be used in a recombinant host for the production of steviol or a steviol glycoside.Type: GrantFiled: December 4, 2017Date of Patent: August 31, 2021Assignee: DSM IP ASSETS B.V.Inventors: Johannes Gustaaf Ernst Van Leeuwen, Priscilla Zwartjens, Viktor Marius Boer
-
Publication number: 20210238235Abstract: The disclosure provides a recombinant cell capable of producing a steviol glycoside, wherein the cell comprises a nucleic acid coding for a variant of a parent polypeptide, wherein the variant has steviol glycoside transport mediating activity, wherein the variant comprises an amino acid sequence which, when aligned with the amino acid sequence of the parent polypeptide, comprises at least one modification of the amino acid residue corresponding to any of the amino acids in the amino acid sequence of the parent polypeptide, wherein the variant has an improved ability to produce rebaudioside M and optionally other steviol glycosides extracellularly if compared with the parent polytpeptide when measured under the same conditions.Type: ApplicationFiled: April 29, 2019Publication date: August 5, 2021Inventors: Johannes Gustaaf Ernst VAN LEEUWEN, Viktor Marius BOER, Priscilla ZWARTJENS, Jos VAN VUGT, René Marcel DE JONG
-
Publication number: 20210147816Abstract: The present disclosure relates a polypeptide having UGT activity, which polypeptide comprises an amino acid sequence which, when aligned with a polypeptide having UGT activity comprising the sequence set out in SEQ ID NO: 2, comprises at least one substitution of an amino acid corresponding to any of amino acids at positions 35, 189, 280, 284, 285, 334 or 373, said positions being defined with reference to SEQ ID NO: 2 and wherein the polypeptide has one or more modified properties as compared with a reference polypeptide having UGT activity. A polypeptide according to the disclosure may be used in a recombinant cell for the production of steviol or a steviol glycoside.Type: ApplicationFiled: June 26, 2018Publication date: May 20, 2021Inventors: Viktor Marius BOER, Johannes Gustaaf Ernst VAN LEEUWEN
-
Publication number: 20210147815Abstract: The present invention relates to a recombinant host comprising a recombinant nucleic acid sequence encoding a polypeptide having at least about: a. 85% identity to the amino acid sequence set forth in SEQ ID NO: 1; b. 85% identity to the amino acid sequence set forth in SEQ ID NO: 3; c. 85% identity to the amino acid sequence set forth in SEQ ID NO: 6; d. 85% identity to the amino acid sequence set forth in SEQ ID NO: 9; e. 85% identity to the amino acid sequence set forth in SEQ ID NO: 11; f. 85% identity to the amino acid sequence set forth in SEQ ID NO: 14; g. 85% identity to the amino acid sequence set forth in SEQ ID NO: 17; h. 85% identity to the amino acid sequence set forth in SEQ ID NO: 20; i. 85% identity to the amino acid sequence set forth in SEQ ID NO: 22; or j. 85% identity to the amino acid sequence set forth in SEQ ID NO: 25.Type: ApplicationFiled: January 27, 2021Publication date: May 20, 2021Inventors: Viktor Marius BOER, Johannes Gustaaf Ernst VAN LEEUWEN, Priscilla ZWARTJENS, Catharina Petronella Antonia KOLEN
-
Publication number: 20210123030Abstract: The invention relates to a polypeptide having cellulolytic enhancing activity, wherein the polypeptide is selected from the group consisting of: (a) a polypeptide comprising an amino acid sequence having at least 60% sequence identity with the amino acid sequence of SEQ ID NO: 2, 5, 8, 11, 14, 17, 20, 23, 26, 29, 32, 35, 38, 41, 44 and/or 47; (b) a polypeptide encoded by a polynucleotide comprising a nucleotide sequence having at least 60% sequence identity to the nucleotide sequence of SEQ ID NO: 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45 and/or 48; (c) a polypeptide encoded by a polynucleotide comprising a nucleotide sequence which hybridises under at least high stringency conditions with the complementary strand of SEQ ID NO: 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45 and/or 48; and (d) a fragment of the polypeptide of (a), (b), or (c), that has cellulolytic enhancing activity.Type: ApplicationFiled: December 30, 2020Publication date: April 29, 2021Inventors: Johannes Gustaaf Ernst VAN LEEUWEN, Loes Elizabeth BEVERS
-
Publication number: 20210040491Abstract: The present invention relates a variant polypeptide having kaurenoic acid 13-hydroxylase activity, which variant polypeptide comprises an amino acid sequence which, when aligned with a kaurenoic acid 13-hydroxylase comprising the sequence set out in SEQ ID NO: 1, comprises at least one substitution of an amino acid residue corresponding to any of amino acids 72, 85, 108, 127, 129, 141, 172, 195, 196, 197, 199, 226, 236, 291, 302, 361 or 464, said positions being defined with reference to SEQ ID NO: 1 and wherein the variant has one or more modified properties as compared with a reference polypeptide having kaurenoic acid 13-hydroxylase activity. A variant polypeptide of the invention may be used in a recombinant host for the production of steviol or a steviol glycoside.Type: ApplicationFiled: July 24, 2020Publication date: February 11, 2021Inventors: Johannes Gustaaf Ernst VAN LEEUWEN, Priscilla Zwartjens, Viktor Marius Boer
-
Patent number: 10913938Abstract: The invention relates to a polypeptide having cellulolytic enhancing activity, wherein the polypeptide is selected from the group consisting of: (a) a polypeptide comprising an amino acid sequence having at least 60% sequence identity with the amino acid sequence of SEQ ID NO: 2, 5, 8, 11, 14, 17, 20, 23, 26, 29, 32, 35, 38, 41, 44 and/or 47; (b) a polypeptide encoded by a polynucleotide comprising a nucleotide sequence having at least 60% sequence identity to the nucleotide sequence of SEQ ID NO: 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45 and/or 48; (c) a polypeptide encoded by a polynucleotide comprising a nucleotide sequence which hybridises under at least high stringency conditions with the complementary strand of SEQ ID NO: 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45 and/or 48; and (d) a fragment of the polypeptide of (a), (b), or (c), that has cellulolytic enhancing activity.Type: GrantFiled: July 27, 2017Date of Patent: February 9, 2021Assignee: DSM IP ASSETS B.V.Inventors: Johannes Gustaaf Ernst Van Leeuwen, Loes Elizabeth Bevers